Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Germany-based Merck KGaA says it is handing over the rights for its cholesterol drug Niaspan outside the US to Abbott Laboratories.
Subscribe to our email newsletter
Abbott will take over marketing and distributing the product. The company acquired Kos Pharmaceuticals at the end of 2006. Merck entered into an agreement in 2002 with Kos of Miami, Florida, for marketing rights to Niaspan worldwide excluding North America and Japan.
Merck sales of Niaspan in 2006 were EUR 7.0 million.